Catabasis Pharmaceuticals to Present Data from the MoveDMD trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting
Business Wire 2-May-2019 8:00 AM
Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present data on
edasalonexent treatment in boys affected by Duchenne muscular dystrophy
(DMD) from the MoveDMD trial open-label extension at the American
Academy of Neurology 71st Annual Meeting to be held May 4 to
May 10, 2019 in Philadelphia, PA.
Richard Finkel, M.D., Chief, Division of Neurology, Department of
Pediatrics at Nemours Children's Health System and a Principal
Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of
edasalonexent, will give an oral presentation titled "Edasalonexent, an
NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple
Functional and MRI Assessments Compared to Control Period in 4 to 7
Year-Old Patients with Duchenne Muscular Dystrophy" during the S51
session "Child Neurology: Bench to Bedside: Progress in Treating Genetic
Disorders" on Thursday, May 9 at 4:25pm ET.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that
is being developed as a potential therapy for all patients affected by
DMD, regardless of their underlying mutation. Edasalonexent inhibits
NF-kB, which is a key link between loss of dystrophin and disease
progression in DMD. NF-kB has a fundamental role in skeletal and cardiac
muscle disease in DMD. We are currently enrolling our global Phase 3
PolarisDMD trial to evaluate the efficacy and safety of edasalonexent
for registration purposes. In our MoveDMD Phase 2 trial and open-label
extension, we observed that edasalonexent preserved muscle function and
substantially slowed disease progression compared to rates of change in
a control period, and significantly improved biomarkers of muscle health
and inflammation. Edasalonexent continues to be dosed in the open-label
extension of the MoveDMD trial. The FDA has granted orphan drug, fast
track, and rare pediatric disease designations and the European
Commission has granted orphan medicinal product designation to
edasalonexent for the treatment of DMD. For a summary of clinical
results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead program
is edasalonexent, an NF-kB inhibitor in development for the treatment of
Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is
currently enrolling boys affected by Duchenne. For more information on
edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com
or www.twitter.com/catabasispharma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005116/en/
